Instil Bio reports Q3 EPS (16c), consensus (10c)

As of September 30, Instil had cash, cash equivalents, restricted cash and marketable securities of $184.5M, which consisted of $9.1M in cash and cash equivalents, $1M in restricted cash and $174.3M in marketable securities, compared to $260.9M in cash, cash equivalents and marketable securities as of December 31, 2022, consisting of $43.7M in cash and cash equivalents and $217.2M in marketable securities. Instil expects that its cash, cash equivalents and marketable securities as of September 30, 2023 will enable it to fund its operating plan beyond 2026.